Heart Failure with Preserved Ejection Fraction: Current Understandings and Challenges

New Therapies for Cardiovascular Disease (KW Mahaffey, Section Editor)

DOI: 10.1007/s11886-014-0501-8

Cite this article as:
Andersen, M.J. & Borlaug, B.A. Curr Cardiol Rep (2014) 16: 501. doi:10.1007/s11886-014-0501-8
Part of the following topical collections:
  1. Topical Collection on New Therapies for Cardiovascular Disease


Heart failure (HF) is the leading cause of hospitalization among older adults and the prevalence is growing with the aging populations in western countries. Approximately one-half of patients with HF have preserved ejection fraction (HFpEF). In contrast to HF with reduced EF (HFrEF), there is no proven effective treatment for HFpEF. The pathophysiology of HFpEF is complex, and the dominant mechanisms leading to symptoms of HF often vary between afflicted patients, confounding efforts to apply “one-size fits all” types of therapeutic approaches. Current treatment strategies focus on control of volume status and comorbidities, but future research aimed at individualized therapies holds promise to improve outcomes in this increasingly prevalent form of cardiac failure.


Heart failure Diastolic dysfunction Heart failure with preserved ejection fraction Diastolic heart failure Hemodynamics Ventricular function 

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.The Division of Cardiovascular Diseases, Department of MedicineMayo ClinicRochesterUSA
  2. 2.The Department of CardiologyAarhus University HospitalAarhusDenmark
  3. 3.Mayo Clinic College of MedicineRochesterUSA